Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JNJNASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$155.90+0.2%$153.68$140.68▼$169.99$375.37B0.418.05 million shs3.48 million shsNVAXNovavax$6.80+0.5%$6.76$5.01▼$17.81$1.10B2.696.30 million shs2.29 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson+0.20%+2.40%+0.94%+1.88%+7.06%NVAXNovavax+0.52%+4.54%-6.40%+8.89%-45.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJNJJohnson & Johnson4.8476 of 5 stars2.35.04.23.93.11.71.9NVAXNovavax4.4908 of 5 stars3.12.00.04.71.10.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJNJJohnson & Johnson 2.55Moderate Buy$170.889.61% UpsideNVAXNovavax 2.29Hold$17.00150.18% UpsideCurrent Analyst Ratings BreakdownLatest JNJ and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.006/5/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.005/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025JNJJohnson & JohnsonLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025JNJJohnson & JohnsonLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$169.00 ➝ $153.005/9/2025NVAXNovavaxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.004/24/2025JNJJohnson & JohnsonBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.004/16/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform4/16/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.004/16/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJNJJohnson & Johnson$88.82B4.22$13.11 per share11.89$29.69 per share5.25NVAXNovavax$682.16M1.61N/AN/A($3.89) per share-1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJNJJohnson & Johnson$14.07B$8.9917.3414.082.3624.42%33.46%13.30%7/16/2025 (Estimated)NVAXNovavax-$187.50M$2.652.5684.940.0638.14%-115.51%29.99%8/14/2025 (Estimated)Latest JNJ and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/16/2025Q2 2025JNJJohnson & Johnson$2.65N/AN/AN/A$22.85 billionN/A5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 million4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJNJJohnson & Johnson$5.203.34%N/A57.84%64 YearsNVAXNovavaxN/AN/AN/AN/AN/ALatest JNJ and NVAX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJNJJohnson & Johnson0.491.261.03NVAXNovavaxN/A2.062.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJNJJohnson & Johnson69.55%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipJNJJohnson & Johnson0.16%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableNVAXNovavax1,990161.97 million160.35 millionOptionableJNJ and NVAX HeadlinesRecent News About These CompaniesNovavax, Inc. (NVAX) Latest Stock News & Headlines - Yahoo FinanceJuly 3 at 5:27 PM | finance.yahoo.comRFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine ApprovalJuly 3 at 1:41 PM | benzinga.comRFK Jr.‘s top FDA vaccine official restricts 2 COVID vaccine approvals against advice of agency scientistsJuly 3 at 6:16 AM | fortune.comModerna’s Shares Gain in Premarket as New Flu Shot Shows Promising ResultsJuly 1 at 2:12 PM | tokenist.comTIs Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?July 1 at 10:01 AM | zacks.comNovavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You TradeJune 27, 2025 | zacks.comVaccines and antibodies up for debate at CDC advisory panel meetingJune 26, 2025 | reuters.comNovavax Approval Process a Potential ‘Harbinger’ of Threat to FDA Integrity: Former RegulatorsJune 26, 2025 | biospace.comBNovavax, Inc. (NVAX) latest stock news and headlines - Yahoo FinanceJune 25, 2025 | uk.finance.yahoo.comWhy Investors Need to Take Advantage of These 2 Medical Stocks NowJune 24, 2025 | zacks.comNovavax Shareholders Approve Key Proposals at Annual MeetingJune 24, 2025 | tipranks.comNotable healthcare headlines for the week: Eli Lilly, Novavax and Sarepta Therapeutics in focusJune 22, 2025 | msn.comNovavax Faces Challenges Amid Stock DeclineJune 21, 2025 | tipranks.comNovavax (NVAX) Ascends While Market Falls: Some Facts to NoteJune 20, 2025 | zacks.comNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowJune 19, 2025 | zacks.comNovavax slips as Citi launches with Sell rating on pipeline concernsJune 17, 2025 | seekingalpha.comNovavax slips as Citi launches with Sell rating on pipeline concernsJune 17, 2025 | msn.comNovavax (NASDAQ:NVAX) Shares Gap Down - Should You Sell?June 17, 2025 | marketbeat.comNovavax (NASDAQ:NVAX) Earns Sell Rating from Analysts at CitigroupJune 17, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 17, 2025 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Novavax (NVAX) and Intuitive Surgical (ISRG)June 14, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJNJ and NVAX Company DescriptionsJohnson & Johnson NYSE:JNJ$155.90 +0.34 (+0.22%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$155.75 -0.15 (-0.10%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novavax NASDAQ:NVAX$6.80 +0.04 (+0.52%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$6.82 +0.03 (+0.44%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
